Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy
暂无分享,去创建一个
M. Picardo | A. Taïeb | J. Seneschal | Katia Boniface | Alain Taïeb | Mauro Picardo | Julien Seneschal | K. Boniface
[1] T. Naka,et al. Dysregulation of melanocyte function by Th17‐related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris , 2012, Pigment cell & melanoma research.
[2] R. Flavell,et al. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.
[3] Rei Watanabe,et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells , 2015, Science Translational Medicine.
[4] A. Christiano,et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). , 2016, Journal of the American Academy of Dermatology.
[5] S. Akira,et al. Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8 , 2004, Science.
[6] M. Picardo,et al. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. , 2006, Pigment cell research.
[7] R. Spritz. The genetics of vitiligo. , 2011, The Journal of investigative dermatology.
[8] A. Xu,et al. Transcriptome Analysis Reveals Markers of Aberrantly Activated Innate Immunity in Vitiligo Lesional and Non-Lesional Skin , 2012, PloS one.
[9] J. Di Domizio,et al. Immune sensing of nucleic acids in inflammatory skin diseases , 2014, Seminars in Immunopathology.
[10] O. Shaker,et al. Role of interleukin‐17 in the pathogenesis of vitiligo , 2011, Clinical and experimental dermatology.
[11] M. Picardo,et al. Beyond vitiligo guidelines: combined stratified/personalized approaches for the vitiligo patient , 2014, Experimental dermatology.
[12] D. Ashcroft,et al. Interventions for vitiligo. , 2006, The Cochrane database of systematic reviews.
[13] M. Falchi,et al. Mitochondrial impairment in peripheral blood mononuclear cells during the active phase of vitiligo. , 2001, The Journal of investigative dermatology.
[14] H. Williams,et al. Feasibility, double-blind, randomised, placebo-controlled, multi-centre trial of hand-held NB-UVB phototherapy for the treatment of vitiligo at home (HI-Light trial: Home Intervention of Light therapy) , 2014, Trials.
[15] Shizuo Akira,et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses , 2004, Nature Immunology.
[16] T. Jouary,et al. Guidelines for the Management of Vitiligo , 2013 .
[17] M. Mansuri,et al. Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics. , 2015, Autoimmunity reviews.
[18] M. Larsabal,et al. Vitiligo‐like lesions occurring in patients receiving anti‐programmed cell death–1 therapies are clinically and biologically distinct from vitiligo , 2017, Journal of the American Academy of Dermatology.
[19] Sheri L. Riccardi,et al. Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. , 2011, The Journal of investigative dermatology.
[20] R. Ballotti,et al. Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients. , 2015, The Journal of investigative dermatology.
[21] Vitali Alexeev,et al. Misbalanced CXCL12 and CCL5 Chemotactic Signals in Vitiligo Onset and Progression. , 2017, The Journal of investigative dermatology.
[22] E. Hoste,et al. S100B Is a Potential Disease Activity Marker in Nonsegmental Vitiligo. , 2017, The Journal of investigative dermatology.
[23] S. Oh,et al. Impact of high‐mobility group box 1 on melanocytic survival and its involvement in the pathogenesis of vitiligo , 2017, The British journal of dermatology.
[24] G. Ogg,et al. Immunopolarization of CD4+ and CD8+ T Cells to Type-1–Like is Associated with Melanocyte Loss in Human Vitiligo , 2003, Laboratory Investigation.
[25] M. Kumaran,et al. A Randomized Comparative Study of Oral Corticosteroid Minipulse and Low-Dose Oral Methotrexate in the Treatment of Unstable Vitiligo , 2015, Dermatology.
[26] W. Westerhof,et al. Association of the koebner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris , 1998 .
[27] M. Cario-André,et al. Follicular vitiligo: A report of 8 cases. , 2016, Journal of the American Academy of Dermatology.
[28] M. Ludovici,et al. Vitiligo: A Possible Model of Degenerative Diseases , 2013, PloS one.
[29] Liangjun Lu,et al. Interferon-γ Induces Senescence in Normal Human Melanocytes , 2014, PloS one.
[30] R. Boissy,et al. On the etiology of contact/occupational vitiligo. , 2004, Pigment cell research.
[31] Daniel R. Caffrey,et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1 activating inflammasome with ASC , 2009, Nature.
[32] P. Muranski,et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. , 2008, Blood.
[33] R. Clark,et al. Response to Comment on “The Vast Majority of CLA+ T Cells Are Resident in Normal Skin” , 2006, The Journal of Immunology.
[34] Jungsoo Lee,et al. A Retrospective Study of Methylprednisolone Mini-Pulse Therapy Combined with Narrow-Band UVB in Non-Segmental Vitiligo , 2015, Dermatology.
[35] Grace Y Chen,et al. Sterile inflammation: sensing and reacting to damage , 2010, Nature Reviews Immunology.
[36] A. Muraro,et al. Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants , 2015, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[37] P. Blanco,et al. Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis , 2017, The British journal of dermatology.
[38] O. Chosidow,et al. Hypochromic vitiligo: delineation of a new entity , 2015, The British journal of dermatology.
[39] M. Pinart,et al. Interventions for Vitiligo. , 2016, JAMA.
[40] T. Taş,et al. The role of helper and regulatory T cells in the pathogenesis of vitiligo. , 2009, Journal of the American Academy of Dermatology.
[41] Dariush Moussai,et al. Th17 Cells and Activated Dendritic Cells Are Increased in Vitiligo Lesions , 2011, PloS one.
[42] I. L. Le Poole,et al. HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. , 2008, The Journal of investigative dermatology.
[43] A. Gottlieb,et al. Tumour necrosis factor‐α inhibition can stabilize disease in progressive vitiligo , 2015, The British journal of dermatology.
[44] V. Swope,et al. Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. , 1991, The Journal of investigative dermatology.
[45] C. Melief,et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. , 2009, The Journal of investigative dermatology.
[46] C. Hunter,et al. CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo , 2014, Science Translational Medicine.
[47] S. Akira,et al. A Toll-like receptor recognizes bacterial DNA , 2000, Nature.
[48] M. Nishimura,et al. Reduced skin homing by functional Treg in vitiligo , 2010, Pigment cell & melanoma research.
[49] Miao-ni Zhou,et al. CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis , 2012, Molecular medicine reports.
[50] T. Jouary,et al. Latent class analysis of a series of 717 patients with vitiligo allows the identification of two clinical subtypes , 2014, Pigment cell & melanoma research.
[51] M. Abdallah,et al. Assessment of tissue FoxP3+, CD4+ and CD8+ T‐cells in active and stable nonsegmental vitiligo , 2014, International journal of dermatology.
[52] Jo Lambert,et al. Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants , 2016, Nature Genetics.
[53] D. Alenizi. Consanguinity pattern and heritability of Vitiligo in Arar, Saudi Arabia , 2014, Journal of family & community medicine.
[54] Henry W. Lim,et al. Vitiligo: to treat or not to treat. , 2007, Archives of dermatology.
[55] J. Richmond,et al. Innate immune mechanisms in vitiligo: danger from within. , 2013, Current opinion in immunology.
[56] Ming Li,et al. Interferon-gamma Inhibits Melanogenesis and Induces Apoptosis in Melanocytes: A Pivotal Role of CD8+ Cytotoxic T Lymphocytes in Vitiligo. , 2015, Acta dermato-venereologica.
[57] S. Passi,et al. Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. , 1997, The Journal of investigative dermatology.
[58] Mark M. Davis,et al. Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma , 2000, The Journal of experimental medicine.
[59] Liangdan Sun,et al. Genetic Variation of Promoter Sequence Modulates XBP1 Expression and Genetic Risk for Vitiligo , 2009, PLoS genetics.
[60] T. Kupper,et al. The emerging role of resident memory T cells in protective immunity and inflammatory disease , 2015, Nature Medicine.
[61] M. Debenedette,et al. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. , 2003, The Journal of investigative dermatology.
[62] T. Tüting,et al. Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. , 2004, European journal of cell biology.
[63] M. Picardo,et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference , 2012, Pigment cell & melanoma research.
[64] A. Necker,et al. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. , 2001, The Journal of investigative dermatology.
[65] V. Engelhard,et al. Mechanisms of Spatial and Temporal Development of Autoimmune Vitiligo in Tyrosinase-Specific TCR Transgenic Mice , 2010, The Journal of Immunology.
[66] D. Sugiyama,et al. Detection of self-reactive CD8+ T cells with an anergic phenotype in healthy individuals , 2014, Science.
[67] H. Lui,et al. Repigmentation in vitiligo : position paper of the Vitiligo Global Issues Consensus Conference ( VGICC ) , 2016 .
[68] W. Westerhof,et al. Local Immune Response in Skin of Generalized Vitiligo Patients , 2000, Laboratory Investigation.
[69] P. Bahadoran,et al. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. , 2015, The Journal of investigative dermatology.
[70] R. Sánchez-Porras,et al. Immunopathogenesis of vitiligo. , 2011, Autoimmunity reviews.
[71] Pingwei Li,et al. The mechanism of double-stranded DNA sensing through the cGAS-STING pathway. , 2014, Cytokine & growth factor reviews.
[72] R. Spritz. Modern vitiligo genetics sheds new light on an ancient disease , 2013, The Journal of dermatology.
[73] M J Watts,et al. Guideline for the diagnosis and management of vitiligo , 2008, The British journal of dermatology.
[74] G. Ogg,et al. High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo , 1998, The Journal of experimental medicine.
[75] W. Westerhof,et al. Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. , 1999, Archives of dermatology.
[76] S. Adams,et al. Lack of functionally active Melan-A(26-35)-specific T cells in the blood of HLA-A2+ vitiligo patients. , 2008, The Journal of investigative dermatology.
[77] C. Baecher-Allan,et al. Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells. , 2012, Immunity.
[78] CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin , 2017, Immunity.
[79] K. Alghamdi,et al. Treatment of generalized vitiligo with anti-TNF-α Agents. , 2012, Journal of drugs in dermatology : JDD.
[80] T. Jouary,et al. Segmental vitiligo associated with generalized vitiligo (mixed vitiligo): a retrospective case series of 19 patients. , 2011, Journal of the American Academy of Dermatology.
[81] H. Rammensee,et al. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. , 2001, The Journal of investigative dermatology.
[82] T. Gao,et al. Vitiligo: How do oxidative stress-induced autoantigens trigger autoimmunity? , 2016, Journal of dermatological science.
[83] M. Picardo,et al. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. , 2007, Pigment cell research.
[84] B. Chandran,et al. IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi Sarcoma-associated herpesvirus infection. , 2011, Cell host & microbe.
[85] W. Westerhof,et al. Review of the etiopathomechanism of vitiligo: A convergence theory , 1993, Experimental dermatology.
[86] T. Jouary,et al. Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms , 2013, The British journal of dermatology.
[87] J. Garioch,et al. An immunohistological study of cutaneous lymphocytes in vitiligo , 1993, The Journal of pathology.
[88] S. Rosenberg,et al. CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. , 2006, Blood.
[89] E. Wherry,et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T cell accumulation in the skin , 2011, The Journal of investigative dermatology.
[90] Xiuli Yi,et al. Oxidative stress-induced calreticulin expression and translocation: new insights into the destruction of melanocytes. , 2014, The Journal of investigative dermatology.
[91] C. Cámara-Lemarroy,et al. The Role of Tumor Necrosis Factor-α in the Pathogenesis of Vitiligo , 2013, American Journal of Clinical Dermatology.
[92] Stephanie A. Santorico,et al. Multiple Functional Variants of IFIH1, a Gene Involved in Triggering Innate Immune Responses, Protect against Vitiligo. , 2017, The Journal of investigative dermatology.
[93] Y. Suzuki,et al. T cell immune responses against melanoma and melanocytes in cancer and autoimmunity. , 2000, Pigment cell research.
[94] A. Taïeb,et al. Special Considerations in Children with Vitiligo. , 2017, Dermatologic clinics.
[95] E. Steingrímsson,et al. Altered E-Cadherin Levels and Distribution in Melanocytes Precede Clinical Manifestations of Vitiligo. , 2015, The Journal of investigative dermatology.
[96] T. Misteli,et al. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2010, Nature.
[97] W. Westerhof,et al. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. , 1996, The American journal of pathology.
[98] E. Shin,et al. Melanocyte‐specific CD8+ T cells are associated with epidermal depigmentation in a novel mouse model of vitiligo , 2013, Clinical and experimental immunology.
[99] A. Gottlieb,et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib , 2017, Journal of the American Academy of Dermatology.
[100] B. King,et al. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. , 2015, JAMA dermatology.
[101] Gang Wang,et al. Dysregulated autophagy increased melanocyte sensitivity to H2O2-induced oxidative stress in vitiligo , 2017, Scientific Reports.
[102] L. Naldi,et al. Randomized controlled trial comparing the effectiveness of 308‐nm excimer laser alone or in combination with topical hydrocortisone 17‐butyrate cream in the treatment of vitiligo of the face and neck , 2008, The British journal of dermatology.
[103] S. Orlow,et al. IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis , 2013, The Journal of investigative dermatology.
[104] A. Taïeb,et al. Vitiligo: the white armour? , 2013, Pigment cell & melanoma research.
[105] T. Jouary,et al. Objective vs. subjective factors in the psychological impact of vitiligo: the experience from a French referral centre , 2009, The British journal of dermatology.
[106] T. Jouary,et al. Pre‐ vs. post‐pubertal onset of vitiligo: multivariate analysis indicates atopic diathesis association in pre‐pubertal onset vitiligo , 2012, The British journal of dermatology.
[107] Wei Li,et al. A novel linkage to generalized vitiligo on 4q13-q21 identified in a genomewide linkage analysis of Chinese families. , 2005, American journal of human genetics.
[108] S. Orlow,et al. Vitiligo inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8 , 2012, The Journal of investigative dermatology.
[109] C. Nathan,et al. Beyond oxidative stress: an immunologist's guide to reactive oxygen species , 2013, Nature Reviews Immunology.
[110] M. Nishimura,et al. A Quantitative Increase in Regulatory T Cells Controls Development of Vitiligo , 2013, The Journal of investigative dermatology.
[111] Vivek T. Natarajan,et al. IFN-γ signaling maintains skin pigmentation homeostasis through regulation of melanosome maturation , 2014, Proceedings of the National Academy of Sciences.
[112] M. Ishii,et al. Coexistence of Langerhans cells activation and immune cells infiltration in progressive nonsegmental vitiligo. , 2014, Journal of dermatological science.
[113] J. Richmond,et al. CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice. , 2017, The Journal of investigative dermatology.
[114] Shi Weimin,et al. Global Activation of CD8+ Cytotoxic T Lymphocytes Correlates with an Impairment in Regulatory T Cells in Patients with Generalized Vitiligo , 2012, PloS one.
[115] R. Spritz,et al. Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP. , 2011, The Journal of investigative dermatology.
[116] V. Swope,et al. Interleukins 1α and 6 and tumor necrosis factor-α are paracrine inhibitors of human melanocyte proliferation and melanogenesis , 1991 .
[117] L. Audoly,et al. Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE , 2007, Nature Immunology.
[118] J. Forrester,et al. CD4 T Cell-Dependent Autoimmunity against a Melanocyte Neoantigen Induces Spontaneous Vitiligo and Depends upon Fas-Fas Ligand Interactions1 , 2006, The Journal of Immunology.
[119] Sen Guo,et al. Oxidative stress drives CD8+ T‐cell skin trafficking in patients with vitiligo through CXCL16 upregulation by activating the unfolded protein response in keratinocytes , 2017, The Journal of allergy and clinical immunology.
[120] Xianlin Han,et al. MicroRNA-211 Regulates Oxidative Phosphorylation and Energy Metabolism in Human Vitiligo. , 2017, The Journal of investigative dermatology.
[121] R. Hegazy,et al. Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: a case- controlled study on eighty-four patients. , 2013, European journal of dermatology : EJD.
[122] R. Buscà,et al. Tumor necrosis factor alpha-mediated inhibition of melanogenesis is dependent on nuclear factor kappa B activation , 1999, Oncogene.
[123] N. Kourda,et al. Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo , 2012, Pigment cell & melanoma research.
[124] M. Picardo,et al. Inflammasome activation and vitiligo/nonsegmental vitiligo progression , 2014, The British journal of dermatology.
[125] M. Nishimura,et al. Mutant HSP70 Reverses Autoimmune Depigmentation in Vitiligo , 2013, Science Translational Medicine.
[126] K. Ezzedine,et al. Type I interferon signature in the initiation of the immune response in vitiligo , 2014, Pigment cell & melanoma research.
[127] M. Picardo,et al. Koebner’s phenomenon in vitiligo: European position paper , 2011, Pigment cell & melanoma research.
[128] M. Picardo,et al. Clinical practice. Vitiligo. , 2009, The New England journal of medicine.
[129] F. Boralevi,et al. Follicular vitiligo: a new form of vitiligo , 2012, Pigment cell & melanoma research.